Giredestrant Reduces Recurrence Risk More Than Tamoxifen, Aromatase Inhibitors
Dec 22, 2025
Results from the lidERA trial suggest that giredestrant could be a new standard of care for early-stage hormone receptor-positive breast cancer. Read more…